131I-chTNT-1/B mAb: Tumour necrosis therapy for malignant astrocytic glioma

Expert Opinion on Biological Therapy

Volumn 6, Issue 5, 2006, Pages 539-545

  Shapiro, William R ^a   Carpenter, Susan P ^b   Roberts, Karen ^b   Shan, Joseph S ^b  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b Peregrine Pharmaceuticals Inc   (United States)

Author keywords

131I chTNT 1 B mAb; Anaplastic astrocytoma; Clinical trial; Convection enhanced delivery; Cotara ; Glioblastoma multiforme; Local delivery; Malignant glioma; Radioimmunotherapy; Tumour necrosis therapy

Indexed keywords

MONOCLONAL ANTIBODY I 131;

CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TOLERABILITY; GENETIC ENGINEERING; GLIOMA; HUMAN; ISOTOPE LABELING; NAUSEA; REVIEW; TUMOR NECROSIS; WEAKNESS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; ASTROCYTOMA; CLINICAL TRIALS; DNA; FEMALE; HISTONES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY;

EID: 33646564104     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.5.539     Document Type: Review

References (28)

1. CBTRUS: Statistical Refort: Primary Brain Tumors in the United States, 1998-2002. Published by the Central Brain Tumor Registry of the United States. (2005) .
2. GIESE A, BJERKVIG R, BERENS ME, WESTPHAL M: Cost of migration: invasion of malignant gliomas and implications for treatment. J. Clin. Oncol. (2003) 21:1624-1636. •• Reviews various aspects of glial cell invasion, and the implications and complications this poses for anti-invasive strategies.
3. COMBS SE, GUTWEIN S, THILMANN C, HUBER P, DEBUS J, SCHULZ-ERTNER D: Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme. J. Neurooncol (2005) 74:167-171.
4. COMBS SE, AHMADI R, SCHULZ-ERTNER D, THILMANN C, DEBUS J: Recurrent low-grade gliomas: the role of fractionated stereotactic re-irradiation. J. Neurooncol. (2005) 71:319-323.
5. WALLNER KE, GALICICH JH, KROL G, ARBIT E, MALKIN MG: Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int. J. Radiat. Oncol. Biol. Phys. (1989) 16:1405-1409.
6. RAMPLING R: Modern aspects of radiation therapy for glial tumours of the brain. Forum (Genova) (1998) 8:289-301.
7. BURTON E, PRADOS M: Management of primary malignant brain tumors in adults. In: American Cancer Society Atlas of Clinical Oncology Brain Cancer. Steele GD, Phillips TL, Chabner BA (Eds), BC Decker, London, UK (2002):262-278. • Overview of primary malignant brain tumours.
8. DEANGELIS LM: Brain tumors. N. Engl. J. Med. (2001) 344:114-123.
9. CHO KH, HALL WA, GERBI BJ, HIGGINS PD, MCGUIRE WA, CLARK HB: Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int. J. Radiat. Oncol. Biol. Phys. (1999) 45:1133-1141.
10. HALL WA, DJALILIAN HR, SPERDUTO PW et al.: Stereotactic radiosurgery for recurrent malignant gliomas. J. Clin. Oncol. (1995) 13:1642-1648.
11. COMBS SE, THILMANN C, EDLER L, DEBUS J, SCHULZ-ERTNER D: Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: Long-term results in 172 patients treated in a single institution. J. Clin. Oncol. (2005) 23:8863-8869.
12. BRADA M, CRUICKSHANK G: Radiosurgery for brain tumors. Br. Med. J. (1999) 318:411-412.
13. CURRAN WJ JR, SCOTT CB, WEINSTEIN AS et al.: Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02. J. Clin. Oncol. (1993) 11:857-862.
14. CHANG SM: Systemic chemotherapy of central nervous tumors. In: American Cancer Society Atlas of Clinical Oncology Brain Cancer. Steele GD, Phillips TL, Chabner BA (Eds), BC Decker, London, UK (2002):193-210. • Overview of chemotherapy for primary malignant brain tumours.
15. SCHNEIDER SW, LUDWIG T, TATENHORST L et al.: Glioblastoma cells release factors that disrupt blood brain barrier features. Acta Neuropathol. (Berlin) (2004) 107:272-276.
16. YUNG WK, PRADOS MD, YAYA-TUR R et al.: Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol. (1999) 17:2762-2771.
17. STUPP R, MASON WP, VAN DEN BENT MJ et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. (2005) 352:987-996.
18. 6-benzylguanine for patients with recurrent or progressive malignant glioma. J. Clin. Oncol. (2005) 23:7178-7187.
19. WESTPHAL M, HILT DC, BORTEY E et al.: A Phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neurooncol. (2003) 5:79-88.
20. 2 monoclonal antibody. Antibody Immunoconj. Radiopharm. (1991) 4:151-161.
21. COOPER EH: The biology of cell death in tumours. Cell Tissue Kinet. (1973) 6:87-95.
22. 131I-chTNT-1/B mAb therapy.
23. CHEN S, YU L, JIANG C et al.: Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J. Clin. Oncol. (2005) 23:1538-1547.
24. EPSTEIN AL, KHAWLI LA, CHEN FM, HU P, GLASKY MS, TAYLOR CR: Tumor necrosis imaging and treatment of solid tumors. In: Handbook of Targeted Delivery of Imaging Agents. Torchillin VP (Ed.), CRC Press, Boca Raton, FL, USA (1995):259-288. •• A detailed overview of preclinical and early clinical development of TNT for solid tumours.
25. 131I-chTNT-1/B radioimmunotherapy adjuvant treatment of hepatic metastases. Cancer Ther. (2003) 1:297-306.
26. KHAWLI LA, MIZOKAMI MM, ZHEN L et al.: Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin. Cancer Biother. Radiopharm. (2002) 17:359-370.
27. 131I-chTNT-1/B mAb.
28. 131I-chTNT-1/B mAb.